This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab

This study has been completed.
Information provided by:
University of Sao Paulo Identifier:
First received: December 8, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted

Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV).

Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.

Condition Intervention Phase
Macular Edema Diabetic Retinopathy Macular Degeneration Drug: bevacizumab Procedure: anterior chamber paracentesis Drug: acetazolamide Drug: brimonidine Phase 2

Study Type: Interventional
Official Title: Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results

Resource links provided by NLM:

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • Intra-ocular pressure variation after intra-vitreous injection of bevacizumab


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • macular edema

Exclusion Criteria:

  • pulmonary chronic problems
  • chronic renal failure
  • intraocular inflammation
  • drug or alcohol addiction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00804921

School of Medicine - Clinical Hospital
Ribeirao Preto, SP, Brazil, 14049-900
Sponsors and Collaborators
University of Sao Paulo
  More Information

Responsible Party: CONEP (Comite Nacional de Etica em Pesquisa) Identifier: NCT00804921     History of Changes
Other Study ID Numbers: IOP After Bevacizumab
Study First Received: December 8, 2008
Last Updated: December 8, 2008

Keywords provided by University of Sao Paulo:
intra-ocular pressure
anterior chamber paracentesis
macular edema secondary to diabetic retinopathy or macular degeneration

Additional relevant MeSH terms:
Macular Degeneration
Macular Edema
Retinal Diseases
Diabetic Retinopathy
Retinal Degeneration
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Brimonidine Tartrate
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Carbonic Anhydrase Inhibitors processed this record on July 19, 2017